Editorial companion

What stands out

Jenny Horne's morning round-up puts two market mechanics on display: analysts make headlines and biotech trials move stocks fast. Wolfe Research's bullish case for Moderna after early melanoma trial data explains why MRNA surged despite a brutal drop in sales and earnings this year. The segment also features Raymond James Financial as the analyst house ringing the bell while its own business reads like a steadier story, which matters when you choose where to put conviction.